1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 AL Amyloidosis: Market Overview at a Glance

5.1 Total Market Share (%) Distribution of AL Amyloidosis in 2017
5.2 Total Market Share (%) Distribution of AL Amyloidosis in 2030

6 AL Amyloidosis: Disease Overview

6.1 Introduction
6.2 Types of Amyloidosis
6.3 Etiology
6.4 Signs and Symptoms
6.5 Clinical Presentation
6.6 Pathophysiology
6.7 Prognosis
6.8 Diagnosis
6.8.1 Differential Diagnosis
6.8.2 Diagnostic guidelines
6.8.3 Diagnostic Algorithm

7 Epidemiology and Patient Population

7.1 Key Findings

8 7MM Epidemiology

8.1 Assumptions and rationale
8.2 Total cases of AL Amyloidosis in 7MM
8.3 United States
8.3.1 Total Incident cases of AL Amyloidosis in the United States
8.3.2 Gender-specific cases of AL Amyloidosis in the United States
8.3.3 Age-specific cases of AL Amyloidosis in the United States
8.1 EU5 Countries
8.2 Germany
8.2.1 Total Incident cases of AL Amyloidosis in Germany
8.2.2 Gender-specific cases of AL Amyloidosis in Germany
8.2.3 Age-specific cases of AL Amyloidosis in Germany
8.3 France
8.3.1 Total Incident cases of AL Amyloidosis in France
8.3.2 Gender-specific cases of AL Amyloidosis in France
8.3.3 Age-specific cases of AL Amyloidosis France
8.4 Italy
8.4.1 Total Incident cases of AL Amyloidosis in Italy
8.4.2 Gender-specific cases of AL Amyloidosis in Italy
8.4.3 Age-specific cases of AL Amyloidosis in Italy
8.5 Spain
8.5.1 Total Incident cases of AL Amyloidosis in Spain
8.5.2 Gender-specific cases of AL Amyloidosis in Spain
8.5.3 Age-specific cases of AL Amyloidosis Spain
8.6 UK
8.6.1 Total Incident cases of AL Amyloidosis in the United Kingdom
8.6.2 Gender-specific cases of AL Amyloidosis in the United Kingdom
8.6.3 Age-specific cases of AL Amyloidosis in the United Kingdom
8.7 Japan
8.7.1 Total Incident cases of AL Amyloidosis in Japan
8.7.2 Gender-specific cases of AL Amyloidosis in Japan
8.7.3 Age-specific cases of AL Amyloidosis in Japan

9 Treatment of AL Amyloidosis

9.1 Treatment Guidelines

10 Unmet needs

11 Emerging Therapies

11.1 Key competitors
11.2 Daratumumab: Janssen Pharmaceutical
11.2.1 Drug Description
11.2.2 Other Development Activities
11.2.3 Clinical Development
11.2.4 Safety and Efficacy
11.2.5 Product Profile
11.3 CAEL-101: Caelum Biosciences
11.3.1 Drug Description
11.3.2 Other Development Activities
11.3.3 Clinical Development
11.3.4 Safety and Efficacy
11.3.5 Product Profile
11.4 Melflufen: Oncopeptides AB
11.4.1 Drug Description
11.4.2 Clinical Development
11.4.3 Safety and Efficacy
11.4.4 Product Profile
11.5 Elotuzumab: Bristol-Myers Squibb
11.5.1 Drug Description
11.5.2 Other Development Activities
11.5.3 Clinical Development
11.5.4 Safety and Efficacy
11.5.5 Product Profile
11.6 Other potential therapies
11.7 Evomela: Acrotech biopharma
11.7.1 Drug Description
11.7.2 Other Development Activities
11.7.3 Clinical Development
11.7.4 Safety and Efficacy
11.7.5 Product Profile
11.8 Isatuximab: Sanofi
11.8.1 Drug Description
11.8.2 Other Development Activities
11.8.3 Clinical Development
11.8.4 Product Profile

12 AL Amyloidosis: Seven Major Market Analysis

12.1 Key Findings
12.2 Market Size of AL Amyloidosis in the 7MM

13 Seven Major Market Outlook

14 United States Market Size

14.1 Total Market Size of AL Amyloidosis in the United States
14.2 Total Market Size of AL Amyloidosis by Therapies in the United States
14.3 Germany
14.3.1 The total market size of AL Amyloidosis in Germany
14.3.2 The total market size of AL Amyloidosis by Therapies in Germany
14.4 France
14.4.1 The total market size of AL Amyloidosis in France
14.4.2 Total Market size of AL Amyloidosis by Therapies in France
14.5 Italy
14.5.1 The total market size of AL Amyloidosis in Italy
14.5.2 Total Market size of AL Amyloidosis by Therapies in Italy
14.6 Spain
14.6.1 Total Market Size of AL Amyloidosis in Spain
14.6.2 Total market size of AL Amyloidosis by Therapies in Spain
14.7 United Kingdom
14.7.1 The total market size of AL Amyloidosis in the United Kingdom
14.7.2 The total market size of AL Amyloidosis by Therapies in the UK
14.8 Japan
14.8.1 The total market size of AL Amyloidosis in Japan
14.8.2 The total market size of AL Amyloidosis by Therapies in Japan

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 Market Access

19 Case Study

19.1 Ptosis and macroglossia in a woman with systemic light-chain amyloidosis
19.2 Cardiac amyloidosis: A case report
19.3 One case of primary AL amyloidosis repeatedly misdiagnosed as scleroderma

20 KOL Views

21 BIBLIOGRAPHY

22 Appendix

22.1 Report Methodology

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

List of Tables
Table 1: Typical Characteristics of Localized Versus Systemic AL Amyloidosis
Table 2: Spectrum of Clonal Plasma Cell Disorders
Table 3: Systemic AL Amyloidosis With Associated Symptoms/Laboratory Abnormalities
Table 4: Laboratory Testing in AL Amyloidosis
Table 5: Guidelines on the diagnosis and investigation of AL amyloidosis in the UK
Table 6: Total cases of AL Amyloidosis in 7MM (2017-2030)
Table 7: Total Incident cases of AL Amyloidosis in the United States (2017-2030)
Table 8: Gender-specific cases of AL Amyloidosis in the US (2017-2030)
Table 9: Age-specific cases of AL Amyloidosis in the US (2017-2030)
Table 10: Total Incident cases of AL Amyloidosis in Germany (2017-2030)
Table 11: Gender-specific cases of AL Amyloidosis in Germany (2017-2030)
Table 12: Age-specific cases of AL Amyloidosis in Germany (2017-2030)
Table 13: Total Incident cases of AL Amyloidosis in France (2017-2030)
Table 14: Gender-specific cases of AL Amyloidosis in France (2017-2030)
Table 15: Age-specific cases of AL Amyloidosis in France (2017-2030)
Table 16: Total Incident cases of AL Amyloidosis in Italy (2017-2030)
Table 17: Gender-specific cases of AL Amyloidosis in Italy (2017-2030)
Table 18: Age-specific cases of AL Amyloidosis in Italy (2017-2030)
Table 19: Total Incident cases of AL Amyloidosis in Spain (2017-2030)
Table 20: Gender-specific cases of AL Amyloidosis in Spain (2017-2030)
Table 21: Age-specific cases of AL Amyloidosis in Spain (2017-2030)
Table 22: Total Incident cases of AL Amyloidosis in the United Kingdom (2017-2030)
Table 23: Gender-specific cases of AL Amyloidosis in the UK (2017-2030)
Table 24: Age-specific cases of AL Amyloidosis in the UK (2017-2030)
Table 25: Total Incident cases of AL Amyloidosis in Japan (2017-2030)
Table 26: Gender-specific cases of AL Amyloidosis in Japan (2017-2030)
Table 27: Age-specific cases of AL Amyloidosis in Japan (2017-2030)
Table 28: Validated treatment response criteria in monoclonal AL amyloidosis
Table 29: Guidelines on the management of AL amyloidosis in the UK
Table 30: NCCN Guidelines on the diagnosis and investigation of AL amyloidosis
Table 31: Daratumumab, Clinical Trial Description, 2020
Table 32: CAEL-101, Clinical Trial Description, 2020
Table 33: Melflufen, Clinical Trial Description, 2020
Table 34: Elotuzumab, Clinical Trial Description, 2020
Table 35: Evomela, Clinical Trial Description, 2020
Table 36: Isatuximab, Clinical Trial Description, 2020
Table 37: Market Size of AL Amyloidosis in the7MM in USD Million (2017-2030)
Table 38: The US Market Size of AL Amyloidosis in USD Million (2017-2030)
Table 39: The US Market Size of AL Amyloidosis in USD Million (2017-2030)
Table 40: Market Size of AL Amyloidosis in Germany, USD Millions (2017-2030)
Table 41: Germany Market Size of AL Amyloidosis in USD Million (2017-2030)
Table 42: Market Size of AL Amyloidosis associated in France, USD Millions (2017-2030)
Table 43: France Market Size of AL Amyloidosis in USD Million (2017-2030)
Table 44: Market Size of AL Amyloidosis in Italy, USD Millions (2017-2030)
Table 45: Italy Market Size of AL Amyloidosis in USD Million (2017-2030)
Table 46: Market Size of AL Amyloidosis in Spain, USD Millions (2017-2030)
Table 47: Spain Market Size of AL Amyloidosis in USD Million (2017-2030)
Table 48: Market Size of AL Amyloidosis in the UK, USD Millions (2017-2030)
Table 49: UK Market Size of AL Amyloidosis in USD Million (2017-2030)
Table 50: Market Size of AL Amyloidosis in Japan, USD Millions (2017-2030)
Table 51: Japan Market Size of AL Amyloidosis in USD Million (2017-2030)

List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Most common types of systemic amyloidosis
Figure 3: Amyloidosis Symptoms
Figure 4: Organ involvement in systemic AL amyloidosis
Figure 5: Organ involvement in systemic AL amyloidosis
Figure 6: Diagnostic algorithm for systemic AL amyloidosis
Figure 7:Total cases of AL Amyloidosis in 7MM (2017-2030)
Figure 8: Total Incident cases of AL Amyloidosis in the United States (2017-2030)
Figure 9: Gender-specific cases of AL Amyloidosis in the US (2017-2030)
Figure 10: Age-specific cases of AL Amyloidosis in the US (2017-2030)
Figure 11: Total Incident cases of AL Amyloidosis in Germany (2017-2030)
Figure 12: Gender-specific cases of AL Amyloidosis in Germany (2017-2030)
Figure 13: Age-specific cases of AL Amyloidosis in Germany (2017-2030)
Figure 14: Total Incident cases of AL Amyloidosis in France (2017-2030)
Figure 15: Gender-specific cases of AL Amyloidosis in France (2017-2030)
Figure 16: Age-specific cases of AL Amyloidosis in France (2017-2030)
Figure 17: Total Incident cases of AL Amyloidosis in Italy (2017-2030)
Figure 18: Gender-specific cases of AL Amyloidosis in Italy (2017-2030)
Figure 19: Age-specific cases of AL Amyloidosis in Italy (2017-2030)
Figure 20: Total Incident cases of AL Amyloidosis in Spain (2017-2030)
Figure 21: Gender-specific cases of AL Amyloidosis in Spain (2017-2030)
Figure 22: Age-specific cases of AL Amyloidosis in Spain (2017-2030)
Figure 23: Total Incident cases of AL Amyloidosis in the United Kingdom (2017-2030)
Figure 24: Gender-specific cases of AL Amyloidosis in the UK (2017-2030)
Figure 25: Age-specific cases of AL Amyloidosis in the UK (2017-2030)
Figure 26: Total Incident cases of AL Amyloidosis in Japan (2017-2030)
Figure 27: Gender-specific cases of AL Amyloidosis in Japan (2017-2030)
Figure 28: Age-specific cases of AL Amyloidosis in Japan (2017-2030)
Figure 29: Pharmacologic Treatment of CF with High/Substantial or High/Moderate Net Benefit
Figure 30: Unmet Needs
Figure 31: Market Size of AL Amyloidosis in USD Million (2017-2030)
Figure 32: Market Size of AL Amyloidosis in the US, USD Millions (2017-2030)
Figure 33: Market Size of AL Amyloidosis in the US by therapies, USD Millions (2017-2030)
Figure 34: Market Size of AL Amyloidosis in Germany, USD Millions (2017-2030)
Figure 35: Market Size of AL Amyloidosis in Germany by therapies, USD Millions (2017-2030)
Figure 36: Market Size of AL Amyloidosis in France, USD Millions (2017-2030)
Figure 37: Market Size of AL Amyloidosis in France by therapies, USD Millions (2017-2030)
Figure 38: Market Size of AL Amyloidosis in Italy, USD Millions (2017-2030)
Figure 39: Market Size of AL Amyloidosis in Italy by therapies, USD Millions (2017-2030)
Figure 40: Market Size of AL Amyloidosis in Spain, USD Millions (2017-2030)
Figure 41: Market Size of AL Amyloidosis in Spain by therapies, USD Millions (2017-2030)
Figure 42: Market Size of AL Amyloidosis in the UK, USD Millions (2017-2030)
Figure 43: Market Size of AL Amyloidosis in the UK by therapies, USD Millions (2017-2030)
Figure 44: Market Size of AL Amyloidosis in Japan, USD Millions (2017-2030)
Figure 45: Market Size of AL Amyloidosis in Japan by therapies, USD Millions (2017-2030)
Figure 46: Market Drivers
Figure 47: Market Barriers

Key Companies
Janssen Pharmaceutical
Caelum Biosciences
Oncopeptides AB
Bristol-Myers Squibb
Acrotech biopharma
Sanofi